Rating Change
HC Wainwright & Co. reiterated its Buy rating on Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) on October 13, 2026.
reiterateNASDAQ:HRMY
HC Wainwright & Co. Reiterates Buy Rating on Harmony Biosciences Holdings, Inc. (HRMY)
HC Wainwright & Co. reiterated its Buy rating on Harmony Biosciences Holdings, Inc.
At publication ·
What changed
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) · reiterate
- Firm
- HC Wainwright & Co.
- Rating
- Buy to Buy
- Price at event
- $37.03
- Market capitalization
- $2.3B
At a glance
Key takeaways
- HC Wainwright & Co. maintained a Buy rating on Harmony Biosciences Holdings (NASDAQ:HRMY) on October 13, 2026.
Market Context
Harmony Biosciences Holdings, Inc. operates in the Healthcare sector. The stock currently trades at $37.03 with a market capitalization of $2.3B.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Harmony Biosciences Holdings, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Harmony Biosciences Holdings, Inc.
Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 13, 2026 | HC Wainwright & Co. | Buy | N/A |
| Oct 12, 2026 | Needham | Buy | N/A |
| Aug 26, 2026 | Wolfe Research | Outperform | N/A |
| Aug 05, 2026 | Truist Securities | Hold | N/A |
| Aug 04, 2026 | Needham | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View HRMY Stock Page
Frequently Asked Questions
What does the Buy rating mean for HRMY?
A rating of Buy from HC Wainwright & Co. reflects the analyst's outlook on Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the HRMY forecast page.